EXACT Sciences Corporation (OQ:EXAS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 441 Charmany Dr
MADISON WI 53719-1234
Tel: N/A
Website: www.exactsciences.com
IR: See website
<
Key People
Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Jeffrey Thomas Elliott
Chief Financial Officer
Mark Stenhouse
President, Cologuard
D. Scott Coward
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
Graham Peter Lidgard
Senior Vice President, Chief Scientific Officer
Ana Hooker
Senior Vice President, Operations
Scott Johnson
Senior Vice President, Research & Development
   
Business Overview
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Financial Overview
For the fiscal year ended 31 December 2019, EXACT Sciences Corporation revenues increased 93% to $876.3M. Net loss decreased 52% to $84M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment income increase of 25% to $26.5M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.43 to -$0.64.
Employees: 4,110 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $9,072M as of Dec 31, 2019
Annual revenue (TTM): $876.29M as of Dec 31, 2019
EBITDA (TTM): -$183.54M as of Dec 31, 2019
Net annual income (TTM): -$83.99M as of Dec 31, 2019
Free cash flow (TTM): -$288.66M as of Dec 31, 2019
Net Debt Last Fiscal Year: $504.82M as of Dec 31, 2019
Shares outstanding: 147,967,507 as of Feb 19, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization